Economic and budgetary impact evaluation of isavuconazole (Cresemba®) versus voriconazole (Vfend®) for the treatment of patients with possible invasive aspergillosis from the perspective of the Brazilian supplementary health system.
Gisele Lemes Veiga AraujoLaura Murta AmaralVinicius PonzioJaime Luis RochaPublished in: PloS one (2024)
Compared with voriconazole, isavuconazole is regarded as a dominant treatment strategy for patients with suspected IA and generates savings for the SHS.
Keyphrases